Cyteir Therapeutics Inc (CYT) Form 4 Filed by Timothy Romberger, Jun 24, 2021
SEC Form 4 · No Market Transaction
Conversion
Conversion of derivative securities.
Equity Position
369K sh
290,388 → 369,448
Equity Change
+27.2%
shares held after vs before
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Timothy Romberger CIK 0001864900 |
Director
|
Timothy Romberger at Cyteir Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at Cyteir Therapeutics Inc
| 2023-02-07 | Award | — | View |
| 2022-02-24 | Award | — | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1 | 2021-06-22 | C - Conversion | 79,060 A | — | 369,448 | Direct |
Derivative Securities Transactions
Footnotes (1)
- F1
- Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date. Show more
Related filings at Cyteir Therapeutics Inc
Institutional Holders
13F holders · Mar 31, 2024
4
institutional managers reporting a position
Largest by reported value
Other insiders at Cyteir Therapeutics Inc
GET /v1/forms/4/0000899243-21-025826
API docs
View Original SEC Filing